JAK inhibitors

photo of a pair of hands that show the skin condition vitiligo

Biotech

Incyte’s vitiligo bet scores ph. 3 wins but can’t shake off Rinvoq

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the prospect didn’t quite live up to Rinvoq.

James Waldron Apr 28, 2026 9:52am

Eli Lilly booth at AACR 2026

Lilly pens $2.3B deal for next-gen JAK inhibitor biotech Ajax

Apr 27, 2026 8:25am

Sanofi

Fierce Pharma

Sanofi inks $1.5B deal for Sino Biopharm's novel asset

Mar 4, 2026 3:00am

Close up shot of the target from a dart game

Lynk sees ph. 3 eczema win as proof of JAK inhibitor's potential

Mar 2, 2026 8:55am

business targets illustration

Lynk targets the JAK pot with phase 3 rheumatoid arthritis win

Jan 12, 2026 8:45am

money flying in

Minghui raises $131M to fund JAK inhibitor launch, ADC trials

Aug 7, 2025 8:15am